NEXT SUPER STOCK Wellgistics (NASDAQ: WGRX) Scaling to $250 Mil+ Revenue next 12 mos. is “Extremely DOABLE” says CEO DO. THE. MATH. This could be worth 4X multiple = $1 BILLION++ valuation = $15.00 stock […]
NEXT SUPER STOCK: Wellgistics (NASDAQ: WGRX) is an emerging leader in $600 BILLION Pharma distribution market in the US. $WGRX is a young company at INFLECTION POINT for EXPLOSIVE GROWTH phase with path to $250 […]
TAMPA, FL / August 27, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) (“Wellgistics Health” or the “Company”), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the introduction of HubRx AI – a fully […]
Next Super Stock Aditxt (NASDAQ: ADTX) Next Super Stock: Aditxt (NASDAQ: ADTX) is a “Unicorn Farm” – buying, building – then monetizing innovative healthcare assets with billion dollar market opportunities. $ADTX is a classic TEN […]
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease […]
Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 […]
Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer patients suffering from painful and debilitating skin toxicities caused by epidermal […]
The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). The new formulation is expected to offer alternatives to both approved […]
Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 — Microbot Medical […]
ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil discussing the company’s drug development pipeline, and upcoming milestones.
Highlights: AI/ML’s subsidiary, Tech2heal, expands its global footprint with second clinical trial contract – conducted jointly by French and Italian University Hospitals. The clinical trial is funded by a European Commission fund. The study includes […]
Highlights: The clinical study, led by the University Hospital of Nice, France involves 30,000 patients. AI/ML Innovations’ subsidiary, Tech2Heal, has been chosen to provide the “technological backbone” for the study. Tech2heal has been awarded a […]
Vancouver, British Columbia–April 26, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory […]
Vancouver, British Columbia– – April 18, 2023- Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for […]
Vancouver, British Columbia– April 11, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
